Deloitte has announced its acquisition of Iperion Life Sciences Consultancy, a dynamic globally-operating firm dedicated to transforming human medicine safety, outcomes and experiences through the application of high-quality, standardized, regulated product information in digital form.

As of May 1, Iperion is operating as Iperion – a Deloitte business. The business will run as part of Deloitte’s Risk Advisory function. Iperion’s co-founder Frits Stulp will serve as a partner within the Deloitte Risk operation, and his counterpart Karel Bastiaanssen has committed to supporting the integration and growth of Iperion in the coming years. The home base of Iperion will remain in Vlijmen, the Netherlands.

Promoting data standardization for better patient outcomes

Iperion was founded six years ago with the ambition to boost innovation in Life Sciences, by promoting the structuring and digitizing of regulated data required for the approval and monitoring of medicines – not only to accelerate speed to market, but to enable greater global collaboration based on reliable, consistent and globally comparable information about medicinal products. Regulated product information includes data for package inserts, information for doctors and pharmacists, as well as formal registration data for medicine approval required by national and international health authorities.

Iperion has been pushing for the introduction of an international data standard since its inception, and is an active proponent of the ISO IDMP (Identification of Medicinal Products) set of standards currently preparing for rollout across the EU – a crucial first step towards global medicinal data interoperability. Under its commitments as a responsible business, Iperion hopes to continue to make a difference under its new ownership, by working with the regulators to improve healthcare, and patients’ trust therein, via greater transparency.

The company is now preparing for its next phase of global expansion with Deloitte. Deloitte, which has worked closely with Iperion in recent years, has witnessed the company’s impressive success first hand and is keen to build on that during this important next chapter.

By combining Iperion’s specialist industry knowledge and passion for its cause with Deloitte’s network and expertise, both parties hope to make a greater contribution to the accelerated approval of new or improved medicines as well as the provision of high-quality information to patients and the healthcare sector.

Shared ambition

Commenting on the announcement, Harvey Christophers, Managing Partner at Deloitte Risk Advisory, said: “Standardized product information is a domain Deloitte has been investing in globally as part of its Life Sciences Regulatory practice, particularly in Europe recently – and in the Netherlands specifically – following the move of EMA. Iperion is an expert in the market and we are eager to see what we can deliver together. The knowledge and passion of Iperion’s young team attracted us, in particular. We are joining forces to help our clients do business responsibly, build trust and have a real impact.”

Aida Demneri, Life Sciences & Healthcare Lead Partner at Deloitte Risk Advisory in the Netherlands, added: “Due to the COVID crisis there is an increased urgency to bring effective medicines to market faster. This requires transformation of regulatory practices towards more agile, data-driven digitalization and standardization of information. That is what we will strive to achieve together with Iperion.”

Speaking for Iperion, Frits Stulp said: “Deloitte and Iperion have been collaborating on innovative digitization projects at pharmaceutical companies for years. The integration with Deloitte is a logical next step to further shape the ambitions and growth strategy of both organizations in this area by, among other things, joining our efforts to implement the data standard ISO IDMP”.

Iperion co-founder Karel Bastiaanssen added: “In the drive to make a difference in this industry we have identified common core values in Deloitte. This merger is a deliberate step in our mission towards standardized and structured data, leading to improved speed of innovation and information transparency. The goal, ultimately, is better medicines and better information provisioning in the Life Sciences ecosystem.”

 

Note: The entity Iperion Information Systems is not part of the acquisition and will continue to operate as Colbright.

Note for editorial staff / not for publication:

For more information please contact:
Marjan Leenders| +31 615 355 205